MedTrace Logo

Controlled Sedation for Cataract Surgery

NCT03401606 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 98

Last updated 2018-01-17

No results posted yet for this study

Summary

This study evaluates the surgeon and patient´s satisfaction who undergoes cataract surgery using either dexmedetomidine or remifentanil as sedation

Conditions

  • Failed Conscious Sedation During Procedure

Interventions

DRUG

remifentanil

remifentanil, 0.25 ng/mL, given intravenous, infusion, until surgery finished

DRUG

Dexmedetomidine

dexmedetomidine, 0.125 mcg/kg/hour, given intravenous, infusion, until surgery finished

Sponsors & Collaborators

  • Fundación Universitaria de Ciencias de la Salud

    lead OTHER

Principal Investigators

  • Luis Muñoz, Md · Fundacion universitaria de ciencias de la salud

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-11-01
Primary Completion
2015-10-30
Completion
2016-01-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03401606 on ClinicalTrials.gov